LEADER 01904nam  2200517   450 
001 9910165027303321
005 20230921114153.0
010   $a1-119-28978-5
010   $a1-119-28975-0
010   $a1-119-28977-7
035   $a(CKB)4330000000009996
035   $a(MiAaPQ)EBC4815063
035   $a(Au-PeEL)EBL4815063
035   $a(CaPaEBR)ebr11354742
035   $a(OCoLC)973222751
035   $a(PPN)243743424
035   $a(EXLCZ)994330000000009996
100   $a20161223d2017      uy|            0
101 0 $aeng
135   $aurcnu||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 13$aAn introduction to pharmacovigilance /$fPatrick Waller, Mira Harrison-Woolrych
205   $aSecond edition.
210  1$aChichester, West Sussex, UK ;$aHoboken, NJ :$cJohn Wiley & Sons Incorporated,$d2017.
215   $a1 online resource (193 pages) $cillustrations
225 1 $aTHEi Wiley ebooks
311   $a1-119-28974-2 
320   $aIncludes bibliographical references and index.
327   $aWhat is pharmacovigilance and how has it developed? -- Basic concepts -- Types and sources of data -- The process of pharmacovigilance -- Regulatory aspects of pharmacovigilance -- International collaboration -- Clinical aspects of adverse drug reactions -- Ethical and societal considerations -- Future directions -- Learning more about pharmacovigilance.
410  0$aTHEi Wiley ebooks.
606   $aDrug monitoring
606   $aDrugs$xSide effects
615  0$aDrug monitoring.
615  0$aDrugs$xSide effects.
676   $a615/.7042
700   $aWaller$b Patrick$f1957 January 30-$0854185
702   $aHarrison-Woolrych$b Mira
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910165027303321
996   $aAn introduction to pharmacovigilance$91907341
997   $aUNINA